Bharat Biotech

Aiming for global equity, Bharat Biotech and GSK will reduce the RTS,S vaccine price by over 50 per cent by 2028 through expanded production and tech transfer

The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022

Hyderabad-based Bharat Biotech will lead Phase 3 trials, regulatory progress and manufacturing for Shigella vaccine altSonflex1-2-3 in collaboration with GSK

Bharat Biotech on Thursday said it has partnered with GSK plc for the development of a vaccine for Shigellosis, a severe form of bacterial diarrhoea. The altSonflex1-2-3 vaccine candidate, developed by GSK and now advancing through a strategic collaboration with Bharat Biotech, represents one of the most advanced Shigella vaccine candidates globally, the company said in a statement. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative Generalized Modules for Membrane Antigens (GMMA)-based platform, and robust early clinical results, it added. "With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries," Bharat Biotech Executive Chairman Krishna Ella said. As part of this agreement, Bharat Biotech will lead the further development of ...

In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years

Bharat Biotech International Ltd on Wednesday said its oral Cholera Vaccine Hillchol has successfully completed phase III clinical trials. The vaccine maker, in a press release, said it has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV. Ogawa and Inaba are two serotypes of Vibrio cholerae O1, a bacterial species that causes cholera. The findings of a double-blind, randomized phase III clinical trial evaluating the safety, immunogenicity, non-inferiority, and lot-to-lot consistency of the Hillchol oral cholera vaccine, compared to a comparator vaccine, were recently published in a journal. The study involved 1,800 participants, ranging from infants to adults, across 10 clinical sites in India, the release said. The participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomi

BBIL's 50,000-square-foot CGT facility advances its mission to deliver life-saving treatments for haematological malignancies and inherited blood disorders

In the last two years, around 200,000 cattle have died, millions lost their milk production capabilities due to LSD nationwide

This initiative comes as a part of the Telangana government's Corporate Social Responsibility (CSR) initiative

Bharat Biotech, based in Genome Valley, Hyderabad, has a portfolio of vaccines and bio-therapeutics, including COVID-19 vaccines and novel vaccines for various infectious diseases

Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter's broad-spectrum anti-microbial vaccine in India and other low income countries. As part of the collaboration, the companies will co-develop and commercialise the vaccine -- AV0328, in India and other licensed territories, Bharat Biotech said in a statement. Alopexx would be entitled to a one-time upfront payment and milestone payments, as well as royalties on future sales of AV0328 in the licensed territories, it added. "Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally," Bharat Biotech Executive Chairman Krishna Ella said. Alopexx CEO Daniel Vlock said, this collaboration brings the company one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial ..

With only one manufacturer currently supplying OCVs worldwide, there has been a deficit of approximately 40 million doses annually

Bharat Biotech in a release said it plans to bridge a worldwide deficit of 40 million doses per year through Hillchol

As firm corrects 'inadvertent' mistake, experts feel it's not uncommon to add new parties to patent filings

Bharat Biotech was working on developing the Covid-19 vaccine as a top priority to ensure product availability at the earliest

Bharat Biotech had then rebuked the BHU study, saying that its indigenously developed Covid vaccine Covaxin has shown an 'excellent safety track record' in various studies

The research conducted by BHU indicated that Covaxin increased the rare risk of stroke and Guillain-Barre syndrome, among other issues

In observational study on Bharat Biotech's Covaxin recipients, about one-third of participants reported adverse events

Bharat Biotech on Thursday asserted that its Covid-19 vaccine Covaxin is safe and devoid of any side-effects amid AstraZeneca's admission that Covishield could cause complications in rare cases. In a statement, the company stated that Covaxin was developed with a single-minded focus on safety first, followed by efficacy. The vaccine was evaluated in more than 27,000 subjects as part of its licensure process, Bharat Biotech stated. It was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects, it noted. The vaccine was also evaluated by the Union Ministry of Health, it said. Besides, safety monitoring (pharmacovigilance) was continued throughout the product life cycle of Covaxin, it stated. All the above studies and safety follow-up activities have demonstrated an excellent safety record for Covaxin without any vaccine-associated incidents of blood clots, thrombocytopenia, TTS, VITT, pericarditis,

Ella takes over the presidency from Adar C Poonawalla, who held the post from 2019 to March 2024